<SEC-DOCUMENT>0001564590-14-005278.txt : 20141107
<SEC-HEADER>0001564590-14-005278.hdr.sgml : 20141107
<ACCEPTANCE-DATETIME>20141107151022
ACCESSION NUMBER:		0001564590-14-005278
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20141107
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20141107
DATE AS OF CHANGE:		20141107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ZYNEX INC
		CENTRAL INDEX KEY:			0000846475
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				870403828
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	033-26787-D
		FILM NUMBER:		141204543

	BUSINESS ADDRESS:	
		STREET 1:		9990 PARK MEADOWS DRIVE
		CITY:			LONE TREE
		STATE:			CO
		ZIP:			80124
		BUSINESS PHONE:		(303) 703-4906

	MAIL ADDRESS:	
		STREET 1:		9990 PARK MEADOWS DRIVE
		CITY:			LONE TREE
		STATE:			CO
		ZIP:			80124

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZYNEX MEDICAL HOLDINGS INC
		DATE OF NAME CHANGE:	20050812

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZYNEX MEDICAL HOLDINGS   INC
		DATE OF NAME CHANGE:	20040120

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FOX RIVER HOLDINGS  INC
		DATE OF NAME CHANGE:	20031126
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>zyxi-8k_20141107.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<body>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:14pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:14pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:14pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, D.C. 20549</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8&#8209;K</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d)&#160;of the </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities Exchange Act of 1934</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (date of earliest event reported): <font style="font-weight:bold;">November 7, 2014</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Zynex, Inc.</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its charter)</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:478.8pt;;">
<tr>
<td style="width:159.6pt;"></td>
<td style="width:79.8pt;"></td>
<td style="width:79.8pt;"></td>
<td style="width:159.6pt;"></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nevada</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">33-26787-D</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">90-0275169</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of incorporation)</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Commission File Number)</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-top:24pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9990 Park Meadows Drive</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lone Tree, Colorado&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">80124</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td colspan="2" valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:24pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: <font style="font-weight:bold;">(303) 703-4906</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:5%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:'Wingdings';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:'Wingdings'">&#111;</font></p></td>
<td valign="top"  style="width:95%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:'Wingdings';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:'Wingdings'">&#111;</font></p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:'Wingdings';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:'Wingdings'">&#111;</font></p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:'Wingdings';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:'Wingdings'">&#111;</font></p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:13.46%;text-indent:-13.46%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;"><br></font></p>

<hr style="page-break-after:always">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:13.46%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Item 2.02. Results of Operations and Financial Condition. </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:13.46%;text-indent:-13.46%;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 7, 2014, Zynex, Inc. issued a press release reporting its results of operations for the three and nine months ended September 30, 2014. A copy of the press release is furnished as Exhibit 99.1 to this report. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:13.46%;text-indent:-13.46%;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01.<font style="margin-left:36pt;"></font>Financial Statements and Exhibits.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)&#160;&#160;<font style="font-style:italic;">Exhibits.</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:102.76%;">
<tr>
<td valign="bottom"  style="width:7.92%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br>No.</p></td>
<td valign="bottom"  style="width:3.32%; border-bottom:solid 1pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:88.78%; border-bottom:solid 1pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.92%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:3.32%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:88.78%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.92%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom"  style="width:3.32%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:88.78%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Press release dated November 7, 2014.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:left;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p>

<hr style="page-break-after:always">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:3.85%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.75%;">
<tr>
<td style="width:7.53%;"></td>
<td style="width:45.06%;"></td>
<td style="width:6.91%;"></td>
<td style="width:40.25%;"></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Zynex, Inc.</p></td>
</tr>
<tr style="height:24pt;">
<td valign="bottom"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 7, 2014</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#8195; Thomas Sandgaard </p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thomas Sandgaard<font style="font-weight:bold;font-size:8pt;"> </font></p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>zyxi-ex991_201411076.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<body>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 99.1</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<img src="g201411071855307011571.jpg" title="" alt="" style="width:133pt;height:68pt;"><font style="color:#000000;"></font></p>
<p style="text-align:center;margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Zynex Announces Third Quarter 2014 Results</p>
<p style="margin-top:13pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LONE TREE, Colo<font style="font-weight:normal;">. &#8211; November 7, 2014&#8212;Zynex, Inc. (OTCQB: </font><font style="text-decoration:underline;font-weight:normal;">ZYXI</font><font style="font-weight:normal;">), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pain creams, announced today its unaudited financial results for the three and nine months ended September 30, 2014.</font></p>
<p style="margin-top:13pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">President and CEO Commentary:</font></p>
<p style="margin-top:13pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thomas Sandgaard, CEO, commented: &#8220;Net revenue for the third quarter was $4,404,000 compared to$3,167,000 for the first quarter and $1,349,000 for the second quarter of 2014. The difficulty with the shipment of consumable supplies that we discussed last quarter has been resolved. On a normalized basis, revenue has stabilized and we are beginning to see growth in orders for our electrotherapy devices. Revenue from the compound pharmacy also continued to grow with revenue of $390,000 for the third quarter compared to $258,000 in the second quarter. The Company generated a net profit of $258,000 or $0.01per share for the three months ended September 30, 2014. </p>
<p style="margin-top:13pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We began shipping prescription TransDermal Pain Creams (TDPC) under the trade name &#8220;Pharmazy&#8221; in the first quarter of 2014. Similar to TENS therapy, TDPC offers very effective, non-addictive pain management with minimal side effects. Zynex compound pharmacy is licensed in 39 states and we are working with third party pharmacies across the US where our licensing is still pending. We have an attractive portfolio of conservative pain therapies and are currently the only company offering both TENS and TDPC solutions on the same prescription pad. </p>
<p style="margin-top:13pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We will be increasing our marketing initiatives to elevate the Pharmazy brand and grow our presence within key pain management markets in the year ahead, and will also selectively add experienced sales reps to support the geographic ramp of compound pharmacy/TDPC in the US.<font style="color:#000000;">  </font>Mike Frabotta who joined us as Vice President of Sales in October will be instrumental in leading this effort.&#8221;</p>
<p style="margin-top:13pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We continue to manage our expenses closely and on October 31, 2014 signed agreements with our landlord that include provisions for terminating our existing lease and establishing a new two year lease for approximately one-third of the space we currently occupy. These agreements reduce our rent expense by nearly $1,000,000 per year. We saw the benefit of the reduced payments beginning in September 2014.&#8221;</p>

<hr style="page-break-after:always">
<p style="margin-top:13pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Summary of Financial Results (unaudited):</font></p>
<p style="margin-top:13pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total net revenue was $4,404,000 for the third quarter ended September 30, 2014, compared to $5,191,000 for the quarter ended September 30, 2013. For the nine months ended September 30, 2014, total net revenue was $8,921,000 compared to $18,331,000 for the 2013 period. The decreases in each period were primarily due to reductions in prescriptions (orders) for our electrotherapy products as compared to the same periods in 2013.These decreases were partially offset by net revenues for sales of our compound pain creams of $390,000 in the third quarter of 2014 and $758,000 for the nine month period in 2014. There was no such revenue in the corresponding periods in 2013. Total net revenue was impacted by the ongoing effect of a year over year decline in the total number sales reps in the field, and industry conditions driven by healthcare reform. </p>
<p style="margin-top:13pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company reported cost of revenue &#8211; rental was $172,000 and $575,000, for the three and nine month periods ended September 30, 2014, compared to $257,000 and $956,000 for the corresponding 2013 periods. Cost of revenue &#8211; sales was $1,211,000 and $2,976,000 for the three and nine month periods ended September 30, 2014, compared $1,289,000 and $4,664,000, for the same 2013 periods. </p>
<p style="margin-top:13pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the second quarter of 2014, the Company recorded a charge of $2,655,000 for the write-off of noncore inventory related to product lines that are no longer being promoted.</p>
<p style="margin-top:13pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company reported Selling, General and Administrative (&#8220;SG&amp;A&#8221;) expenses decreased to $2,609,000 for the quarter ended September 30, 2014 compared to $4,713,000 for the quarter ended September 30, 2013. For the nine months, SG&amp;A expenses were $9,012,000 in 2014 compared to $16,699,000 for the 2013 period. The reduction in both the three month and nine month periods reflect reduced headcount and lower sales commissions.</p>
<p style="margin-top:13pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generated a net profit of $258,000 or $0.01 for the three months ended September 30, 2014, and a net loss $6,724,000 for the nine months ended September 30, 2014; versus a net loss of $738,000 or $0.02 per share, and a net loss of $2,798,000 for the corresponding periods in 2013.</p>
<p style="margin-top:13pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s cash balance and outstanding line of credit as of September 30, 2014 was $319,000, and $4,541,000 respectively, as compared to a cash balance $323,000, and outstanding line of credit of $5,820,000, as of December 31, 2013. As reported on Form 8-K filed with the Securities and Exchange Commission on July 18, 2014, Zynex received notice from Triumph (the &#8220;Lender&#8221;) of an event of default under the Company&#8217;s Loan and Security Agreement with the Lender dated December 19, 2011, as amended ( the &#8220;Credit Agreement&#8221;). The Company and the Lender are continuing to negotiate the terms of an accelerated repayment of the amounts outstanding under the Credit Agreement and the Lender has continued to make additional loans to the Company. No assurance can be given that the Lender will continue to make additional loans or that the parties will agree on a repayment plan acceptable to the Company. The Company is actively looking to raise capital from new lenders or investors.</p>
<p style="margin-top:13pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Webcast Details</font>: Friday, November 7, 2014 at 9:00 a.m. MT &#8211; 11:00 a.m. ET</p>

<hr style="page-break-after:always">
<p style="margin-top:13pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To register and participate in the webcast, interested parties should click on the following link approximately 10-15 minutes prior to the webcast: </p>
<p style="margin-top:13pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">http://www.visualwebcaster.com/event.asp?id=100936</font></p>
<p style="margin-top:13pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Please note: questions can only be submitted via the webcast user interface. Parties without access to the internet may join the presentation in listen only mode by dialing the toll free number provided below.</p>
<p style="margin-top:13pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Phone Access Details</font>: <font style="font-weight:normal;">Toll Free Dial-in Number: </font>888-364-3109, <font style="font-weight:normal;">phone access passcode: </font>8055032</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About Zynex</p>
<p style="margin-top:6pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Zynex, founded in 1996, operating the under its Zynex Medical subsidiary, engineers, manufactures, markets its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company&#8217;s proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex Medical&#8217;s product lines are fully developed, FDA-cleared and commercially sold world-wide. Zynex Medical also operates a non-sterile compound pharmacy providing topical and transdermal pain creams. Zynex Billing and Consulting division provides medical billing and consulting service for offices and hospitals. </p>
<p style="margin-top:13pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For additional information, please visit: <font style="text-decoration:underline;">www.ir-site.com/zynex</font><font style="font-weight:normal;">.</font></p>
<p style="margin-top:19pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Safe Harbor Statement</p>
<p style="margin-top:6pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain statements in this release are &#8220;forward-looking&#8221; and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital or augment our liquidity in order to continue our business, the success of our compound pharmacy and international expansion efforts, our ability to engage additional sales representatives, the success of such additional sales representatives, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation and other risks described in our filings with the Securities and Exchange Commission including the &#8220;Risk Factors&#8221; section of our Annual Report on Form 10-K for the year ended December&#160;31, 2013.</p>
<p style="margin-top:13pt;text-align:justify;margin-bottom:0pt;text-indent:0%;color:#;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contact: Zynex, Inc. 303-703-4906</p>
<p style="text-align:center;margin-top:13pt;margin-bottom:0pt;text-indent:0%;color:#;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">###</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g201411071855307011571.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201411071855307011571.jpg
M_]C_X``02D9)1@`!``$`8`!@``#_X0!V17AI9@``34T`*@````@``8=I``0`
M```!````&@```````9*&``<```!`````+`````!53DE#3T1%``!,`$4`00!$
M`"``5`!E`&,`:`!N`&\`;`!O`&<`:0!E`',`(`!)`&X`8P`N`"``5@`Q`"X`
M,``Q``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC+B!6,2XP,0#_VP!#``("
M`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@,#`@(#`@("`P0#
M`P,#!`0$`@,$!`0$!`,$!`/_VP!#`0("`@("`@("`@(#`@("`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1
M"`!<`+$#`1$``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<(
M"0H+_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!
MD:$((T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I3
M5%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6F
MIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T
M]?;W^/GZ_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$`
M`@$"!`0#!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S
M4O`58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC
M9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.T
MM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`
M#`,!``(1`Q$`/P#]_*`"@`H`*`"@`H`*`"@`H`*`"@"I>7]CIUO)=7]Y;6-K
M`I::XNIXK>WA5026EFE94B4`'EF`XHZI+5]$M_*R!M13;:BH[MZ)>KZ'S9XL
M_;%_9[\)SS6)\>VOBG5X"RG1/`-EJ'CG5&D5BOE>7X9M;N")RXV_OKB(`\,0
M:]7#Y'FF(CSK"2H48KFE4K-481BK7;=1IV5ULGN<=7,,'1?+*O&4U=*$/?E=
M1YGI"]O=7-K;W=5<\NO?VSO%.J;A\.?V8/C-XFB(S!J7B.#1_`VG2J#CS0+^
MZO+I4!ZJ]O&?0\BNC^QJ-*,I8G.<%2Y+*4*<W7FKJ\;**C&5U;6,K*^KN<_]
MI3E;V.`Q$H<O,ISA*FK_`&8J/+.:E+=*48Z7;LU8X34_VE/VS+J1UT?]G[X9
M^'8QD*?%/Q":]E7(RA9+:33@<GC@X)4C(Q6_]G9#3IJI/-:U>ZNO84'9:I6D
MVI)27;F\TV-8O%\L92P\::349Q;3E&6MTI<\::2M;WW&2?V=4GP][^T/^WY#
M+B+X<_!"4;?]58ZA<78!Z\NWC)#D#\..N:VP^`X:KIQ6.Q5*4;-N:4=/)+#S
MTO\`-;>9,<3BVFU*FY1=E#DBYR\XI8NS76]ULSFK[]K']O?0R9;_`."7@2\M
MUC\QGL=&URYA*@%C^]L_&#G.%Z;>XQG(K>&4<.U.>-/-*G-"2C:52E%R=TER
M0E1A*=]E9;^2,XX[$\BJ33C%5/9N/U6HY*6EKJG6J<L7=+F>BZV9E6?_``4[
M^*GANXCB^(OP!LHHUXG;2]6US0+@D9'[N+6-+O8E/RM\K3GI6TN$\/43>%Q\
MG:UG*$*D=K_%3G&_JDK==36&8*4II2I2:DXQCS2IRM&7))OGC[UI6BG%.,I7
M29]$>`?^"FG[/GBB6"T\5V_BWX;W4NT-<:[I::MH<3D#.[5O#LUX\488D>9/
M:P+@9;:*\ROPMF-)7HRI8FWV82<9_P#@-103]$V_(Z(8NT5[:C.@[7=K3BGK
MIS0N]+;N*6JZZ'W9X1\;>#_'VD0Z]X)\3Z%XJT:=4:/4=!U.TU.V!==RQRO:
M2OY$P'6*0(ZD$,H((KP*U"MAJCI5Z4J-2.CC.+B]--GT[-:=CIA4IU$I4YJ2
MTUBT]]MMCJ*R+"@`H`*`"@`H`*`"@`H`*`"@`)`'H!SSP`!1M\@/*O'GQG\`
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M4FF]+>EBH_\`P3>_:XNT,]YKGP]W[0!Y_C/Q)>,%!RH,TFAMP6)/)/)/K4RX
MNHJ34,OYH.WQ5&GTTDHQ2;BE;1).VAG'+LXITW3I5<#1COR0HRMS6W]^,KN3
M6LI-OSL<SJ/_``3Q_:]TM#-!9^"-7\L%BFF>.9(IAM`*JAU.QLH\DDC)E4#'
M7FMJ?%F!4K3P4HP6C=.3O):6LI<O+;6_,Y7TLB?J6?PNXU<%)QM9>Q4;Z.ZN
ME%KMK:_1VW\MUGX3_MD?"???7_@GXL:19VF'DU'PQJ>I:_81;<;V,OAO5+]-
MBH!EGC"`=3BO2AG/#V,;HRJ>SC*.LJ]*G[/3[$DUS+ETY9<MGM$XVLXP:7/E
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M0`KP7T$T)R,J#BLITJ&.HSIXO"VY?=E"K%*<+_"Z<_G[LZ4K7[7L/"8V.+3Y
MH3P5>,E#G^'WWM&[NG)ZVIU%).UU=JR_8C]D7]O?3/C!>Z=\-OBO#IWACXEW
M(2WT+6+/-MX:\<SHAS:V\,TC'1/$K(I<6+2/#<G?]D</BV7X?.<BEER^L8>4
MJN$;L[KWZ.UN=I).+=[225MI*]F_9HUYJ2I5TE>RA46BF^TH_8GIHKN,G?EL
M_=/THKYT[`H`*`"@`H`*`"@`H`*`.:\5>+_#O@G1[S7?$VK66CZ781^9<7=[
M,(8D!.V-!P6EFD?"1PQ+)+([!(T=B!5TZ52K.-*E!U*DMHQ5WIJ_1))MMZ)*
M[:0I2C"+E.2C&.[;22Z+5^>B/@WXR_M1266D_P!HZKX@N?@]X(O8W.E3O:17
M?Q=\;P!3\WA+PK*&_P"$9L)!D#4=01[A<AL6;#%>_@,GE5:]G3CC:\6N9-N.
M#HNU^2K6C=U:J?+^YI^[;>4HMV\NMC:C<52C*G3=.4U'E7UFHELX0FU&C#HZ
ME:SO=*-U<^"?#7Q"^/WQSU+4=`_90^&>H>%O#]U<&#7_`(F:G=1W>O7\S,4F
MN?%7Q/UM7A@NR-[-9:0UY=*"%0DCCWL1#*\#2A_;&(6+Q4+N&&I+EI4MG&-*
MA#W::T4>:IKO=<KL>?1]O5=58/#)JK_$K>T:3E>2<*N)=JE:RU:H6@KJ,7;F
M/IOX;?\`!+?3+FZ'B+X_?$K7?&>LW;?:+[1/"ES=Z5I[RMAGCU+Q3J7GZUK&
M'+`M%_9@/88Z^5BN+,9.T<%2AA(1=[M*I/Y7BH135K\L-^NQW4<J5E]8JM;7
MI4;TJ=DN51E-?OJJ6Z<YJSV2/T'^'/[.?P0^$]O%#X!^&?A/0)H@`=1BTJ&[
MUF9@-OF3ZYJ/VC4)I"`,LUT>E?.5\7B<5)SQ%>=:3_FDVNNB6R6KZ=7W/0H8
M7#856P]"%&RM>,4I6[.7Q->K/:!%&N,(N1T)&2,<=3D]A7/MY6-Q_3VQ^&*`
M"@`_S^5`$$EM!+_K(D8CHV,,.@R'7!!X'0T?H&WR/GGXO?LK_!;XT6<\7C/P
M3I%YJ+Q.D&O6L(TOQ+9LP($EIXAT]8[Q65L$).]Q#D?-$PR#TX3&8K`U8U<+
M6G1G!W2C)J+\I1O9IK1I]#FQ.#PN-BH8JA&NH[<RU7I)6=M-5>SML?B3^TM^
MPUX^^`4=[XK\)W-[X\^&5EOFOG>W0>*_"=D,?Z1JUM:J(M3TF($;M0LU01J-
MUS;P+F0_>Y3Q)1Q\HX7'J.'QDW:%9>[2J2UM&:VA)[*6S=NK/`J8;&9,HU*-
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M5-?N%G\<^#KU_!WC27`5K_4+"W@N-.UXQK]PZIH]Q97,F,*+G[6J@*@%?E.<
M8'^S\=5I17+1E^\I:KX)7LM+6Y6G'Y7/9P=:52G.%1WJX>;IR?>R4HSMTYH2
MBVNCNEHCZ^KRSK$)"@DD*%&23P`!U)/8"@#,_MS1!_S&-+&./^0A:#&/^VU`
M"?VYHG_08TK_`,&%I_\`'J`$.OZ$KP1G6M)62YGCMK9#J5F'N+B3(BMX%,V9
M9VVMM106.TX'%`%F74=/@GAM9K^SAN9Y!%;V\MU!'/-*=V(X8F<-)(=C_*H)
M^1N.#0!=H`\L^*?Q6T#X7Z+'>Z@+F_U;4KI-*\.>'-+C6YUSQ'K<ZDV^DZ19
MEAYDY`WRS2%8+6$-/.ZHOS=.%PM7%SE"ERQA3CS5*DWRTZ4$[.=271=$MY/2
M*N95JL</3E4GM':*WD^D8KK)[)=S\COC?^T?KR^,K/0['3T^)OQZO;L67A;P
M/H<,GB/P5\*=0N052STW3HE'_";?$=%_X^;R8>5:X;>UO`AAKZ[`Y50I4/;U
M:JPF5VM4JU/W=?%1=G&[5WAZ$K>Y33]I4TYH]3PZV(G4E1<_=Q3E*-.,5SQI
M-U(WI1IR<8U\1%1Y9UG^YIZM;>]ZM\"/V`)?&NI_\+8_:N\2-\0O%-_.\LG@
M2UUL:GI%A.C`_9/&&MV,N-7N8#A3I&G/;:=;Y,;&Z7@<&.XB<8?4\GI_4,)&
MUIQ7)4E9?92O[./1ZRG))-S6QU4\M]M*-;&I<]^9THO1RT2E6FK.M.T5?:G?
MX8V;O^K6C:)H_AS3++1=`TO3]%T?3($M=.TO2K.WT_3[&VC&$@M+.TCCAMXE
M`^[&BCVKYAMMN4FY2;NV]6WU;?5GKI)))*RCHDMDELDNB78NW-U;64+W-Y<0
M6EM$"TD]S-';PQJ!DL\LK*J``=212`?#-#<0Q7%O+'/!/&DL$\+K)#-%(H:.
M2*1"5DC92"&4D$$$&@"E+K&DP2/#-JFG0RQ-MDBEO;:.2-@,[71I04;!'!`H
M`@D\0:!#&\LNMZ1%%$C/)))J5DD<:(,L[NTP"(H!))(``H`T7NK6*$7$ES!'
M;L@D6=YHTA,9`8.)&8*4*D'.<8.:`"VNK:]@2YL[B"[MI-WE7%M-'/`^QVC;
M9+$S*VUU93@G!4CJ*`)Z`,^]U;2M,V_VCJ>GZ?O,:I]MO+:TWM+((8@OGR)N
M+S,L:@=68*.3B@!-3TVVU2TEM+F.-TDC>/$B+(A5U*.DB."LD3*Q5T8%65B"
M"*/T#;_(_F]_;5_9[M_@5\3HKSPS8BS\`>/3J&I:/90H1;^'=?M)(GUSP_`>
MD6GLMQ#?6<?\$5Q+"ORVHK]'X=S*6.PDZ->;EB<'RQYI/WIT7=0;ZN4&N1O5
MV2NVSQE1^I8E8>E!1PE=5*D$D_W=5.+J0O>R@T^:"2T;DMD?(\L@DL+)2S%[
M:6\A"E@0(7,$Z!5Z@"1YNO'/'2O?LEJM&]]/N=]O*UM-7U%3@Z>*Q+22A6A1
MG=)WYX\\'=[-\L8;:Z:GZJ?\$E]7NU\8_'C05=CISZ)X"UAD"@1K?PW7B/3]
MV_.?,-NV"/1!_=KY#C&DHQRNKM*4*T;7Z*:::C;3=ZWUT)RV:EF.;)3C)1E0
MC9:-.%*TM.NKLY:.Z4;:(_;>OB#W#F_&&@W/B?PIXC\-V6LWOAV[US1=1TJU
MU[3HX);_`$6XOK66WAU.SBN5:*2YMG=94612I:,!ABC]`V/RR_X=73DDM^U+
M\7&9B69O)M1EF)9FPM\`,L2<``>@H`\U^+G[!7@[X&?#WQ)\2_'W[57QA70O
M#UA+)#9VSV-M>ZOK$J-%H^CV9EN93+/=7IBCV(F[9O;=&J,ZFWR#]"C_`,$T
M_P!FOQ#XUU"Q_:4^*MWKFHZ'HMU=#X.Z'K^HW]ZDM_MEM+SQPT%W.R[8XFDM
M;)POS9GE!VD"C;Y!^A[O_P`%&?V9O%GBG1;;X_\`PAU/Q'9>./A[]DUCQ+H&
MB:C?H-8TO0&%Y8>+M$TZ&0QKXP\//")AY<>Z\LDDB(>6V@24V^0;>5CT']F+
M]NSPC\5?@-K7C#QUJ-EHOCSX8Z5;K\1;"W"G^T8BBPZ7XJ\/V2G==VNN3>7#
M#;19,>H3&T'!B+ZT*%7$UJ>'H0<ZM1\L8K[VV^D8I.4F](Q3;V,ZM6GAZ4ZM
M67+3I*\G9O3R23;;=DDDVVTDF?$OQA^,OQ&\4>.;#P[X4TZ[U+]H7XG0C1?#
M^B:>YGD^$'@G5U^TVGAW297S%9>,;W3P;_7=;8(+.+S)-R)#`(ON<)@\+@L-
M*IB'%Y9@I\TI73^NXJ":51JZ4J$6N7#4F[2<7.:MJ_EJE26-GS3<_;XJ/+3H
MPJ/]W!74J5.3A&,'**;Q5=?O(PDJ<7%[_=?P3_9"\,?LU_"/QKK]U)!XA^,>
MK>!_$#>(?'&'$FEO+I-S++H?A*:;$VFZ3%,`9+G<MS?2IY]RV/+A@^6S3-\3
MF=1NHW3P\7>G14GR1WM)K:51IZRLNR26A]!@\''"KGE:6(E&,932M%1BK1IT
MU]FG"UHI^\_BDW)Z?C]^R1^UKXR_9F^(=UK'BMM=UOX,_$7Q-JUAXNBN'NK]
MK?5]*G@@N_%>@22N_G:[I=K=:=]OL@1)=V,D)VF2*W>O*V^1V[?(_IKT'7=&
M\3Z+I7B+P[J5GK&A:W86NJ:1JNGS)<66H:?>PI/:W=M,A(DBDB=6!]\$`@@`
M'YY_\%2[^_L/V8=0-C?7M@9_$&G6UPUE=3VK3V\L<ZR6\Q@=3+`ZG#1ME2.H
MH#;R/K']F;C]GGX*#GY?AEX-`R<X"Z'9@#GL``/PH`_$CP=\&==_:;_;&_:"
M^'U[\6/'7@BP\.7.I>(;2YT34+B[9R-3M=.%D;:[NA'%`%D#`H5(VXZ$`'Z`
M?5M[_P`$H8]0L[K3[W]IWXKW%G>V\MK=6\]K930SV\Z&.6*6&6]*2QLC$%6!
M!Z$$4;?(#]%?''P3\.^/_@]_PI[6]1UB"QA\.Z;HVG^)-+O)M.\0Z5J.CV,5
MKIGB'3[RUD0PZA#-"DQC+&*56DAE5XI75@#\>?V:_C3X\_83^.NN?LS?M"7\
MK_#CQ!K1O=#\67,EPVEZ1>:U=2)IWCG29[IV*^#M>G&S4X"Y;3=0$LDF-ER9
M#;Y!L?M+\4_BKX,^#OP^U[XE>--5@L?#>A6!NS*LD;RZE/(G_$OTW2TW?Z7?
MWLQ2*"-"=Q?<2$5F!M\@/RS_`&8_AQX^_;.^+$_[6OQWBOK+X9:3JL<GP7^&
MDUQ<C1;@Z1/)_96MS6)=8KFRTZ0M)'</&3=WK2SC]U&@4V^0'[)]/;'X8Q0!
M^;'_``4S\.VE]\"FUJ2.+[5X>\6^$]1LY=O[V-KZ\FT"[56Q\HEM]2PV.OE+
MFOH>%YN.;1BM%4HUHOTC'G7XP7RN<..M&&'J65X5Z:5^U2].6W]V7FKI7[K\
M"99%@BDE8$B)2Q`X)QT&?<\5^CP@YSC!:.3LCFQ.(AA,/6Q,TY0H1<W%;NVR
M7:[LKG[7_P#!)?P!=:;\//B9\4+ZW>$>-_%5GH&C221A?.TOP=!=?;;JW?J]
MO)K>LWUL>PDTEP.0:^#XQQ*JYI'#1^#!4HTUO>_Q._3LX];/=WTXN&:-182O
MC:B49X^JZMEVO*SZ):RDOD?K=7R9](%`$4\\-K#-<W,L5O;V\4D\\\SK%#!#
M$ADEEED<A8HD169F8@*%))P*`/PX\9:EK?\`P4H_:<M_A]X=N;VV_9@^"]^+
MKQ+JT#2Q6WB>]CD>*::)UPLE[JK(]I9KR8-/6>YPK70(-OD'Z'[<Z+HVE^'=
M(TS0=$L;?2]'T>QM=-TS3[2-8;:SL;*%(+:WAC4`*B1(H'TR>31MY6#;Y&D<
M8.<8QSGICOGVH`_G:_:-^&_PS^!/[3/C_P`7^#6CCT.'PO8>,7\$%!#I6E>-
MO$>IW4VEZ/#''(L5SH4VI6$?B`64B!;((%B&SR1%]EPM@;JIBYQO[;FH05VK
M0C9UIW6J;?)3AI:_/[RM9^%FV(O4P^"A%W<XU)RT48^S7.HRE))+93T=WRJ*
M6K:_0#_@GQ^SW-X7\*W'[0/Q!MY+WXH?%B&75-.N-3C9K[P_X-U*47=L$$Q8
MV^I:YB'4+E@0RVQT^U^402*_!Q%F3Q.)>#HSB\'@VH14/AE.,5&3NK74&N2"
MM9).U^9LZ\NH\M/ZQJO;)>S3NK4W>2E*+VJU6W4JVTNXI)<I]X_$DA?AYXY^
M7<%\(^(OEXYQI%WQSQ7SAZ1^,?["_P`!/!G[1O[+?QP^'7C.-X`WQCU;4?#.
MOVJ(^I^$?$L.B6,=CKVEL^`74-Y5Q;L0EU;/+;R$+(&1[)=`,7]E+X]>./V)
M?BWJ?[*G[1DCV/@.?5@OAKQ#,\K:/X6O-6N6&FZ_I%W.`7^'.O2%F<'']F7K
M2^8$Q=K&MOD&Q]=_\%5)(W_9<N)$=7C?Q)I+QNC!D=724HZLN04(((89&#GI
M0!]?_LS?\F\_!7_LF?@[_P!,EG0!^&?@G]H9?V;?VROVC/&'_""Z[X]FUJZU
M#P_'IN@)=R7.G(FJVU^U_/':6L^Z)_+\G,BJ%Y*DDG:;!M\CZPO/^"K>IBWD
M73/V;?'TVHLT$5G%?0ZQ;6C333Q1#[3/%H,KPQ!'9MRQ.<J!CG(`/U_TR[:^
MTW3[YX6MGO+&TNWMWR'MVN((YFA?(!W(7*G('*T`?(/[;?[-7@7]H/X2ZG+X
MAU32O!_B?P)8ZCKWA;Q_J:JMEH:16_FZIIFON,-/X6U"W@5+J($M&\<%S"#+
M;JDAMY!^A^)OP)UW4_VLOB'\#OV;OC1\4E@^$_PZ%Y;>&])DDN4G\?SZ,['3
M?#TVJR/^^U*?3$^SVCW;+(MA;M;0*TTAWFP?H?TVZ1I&F>']+T_1-%L+;2](
MTFSM]/TW3K*)(+6RLK6)8;>V@B0`1QI&BJ`/3UH_0-O*QHT`?EO_`,%0/&=K
MIWPIT+P<LRM?^*_%^F!(`1O&G^&H9M8OYBO78MV^E1Y_O3`=^/IN%:$JF85*
M_P`,,+2E?_%5]R*^[G?_`&Z<F+VH4^]13[65-.5]G]IQ5M+W>I^*/@3X<>+/
MC+\0/"GPK\$6QGUWQ1J"127!1WM=%TJ'$FJ:]J90'RM.T^Q\VYD+??*Q1)F6
M:-6^RS/'/+L#.M&<:=6M>G!R3=HV?/*"2LY[1C>RUD]>5GS>:0GC\5A<II.T
M7^^KN^D8I/DA))K27O2M>[2BXW=C^KKX8?#OP]\)OA]X1^&_A6$PZ%X/T2ST
M:R9P!/=-;INN]1NRO#WU[>O<7D[C[TUU(W>ORRO6J8BM4KU7>I5DY2WW;O97
M;:2V2OHM#ZRE3A0ITZ5-<L*45&*\HJR^>FKZO4[RLBPH`_*+]OOX\>+_`!3K
M.D?L;_`))]6^)?Q#,$'CF\TQVV^&O#-TH>33KV[B.+!9[,FZOYF9/)L4$9.^
M]44;?(/T/M?]F?X#^#OV;/A3H7PZ\.R6L]Y#&NH>*=<)B6Z\0^);F-#J.I7#
M9#>5Y@\J",\1PQ1H`,&C;Y!M\CW_`.TVP('VB`$L%4>;&"68X50-WWB>`*`(
MK]_*L;IQU6"0C'^Z0*-OD!_.+XZT*\^./[;VK_#K4Y9#IGB;XU6FAZDB.0P\
M.>&;:&WU")3D8`\.Z/J`4#!#73D$$@C]&P]9Y=PS"K12C.-#VB=K_O:KLI/1
M_"Y7U7+=*YXV)P[G7<N:3J5I0H^ZTN6E[13EI:S]R,E)N[LW'9G](,$$-I!#
M:VT4<%M;11P6\$*+'%##"@CBBBC4`)&D:JJJ````!TK\YV/9V\DNAQWQ*W#X
M=^.MF=P\(>(MN,$Y&D7>.#0!^:?_``21X^$GQ<'I\8=4Z^^DZ=WP/2GT0'T]
M^V3^R;X=_:C^'KV42V>D_$OPS;W=SX"\431`*DTJ;KGPSKCHI>X\,ZF8XXYD
MPS6\HBNX07A9)E^@?H?A=XY^/_C./]F7QM^RC\;+;6+7Q_\`##Q5I%CX/.J+
M)/J<&CZ>)X-4\+:]<MGS8=+B%O/I>I!Y%NK*ZAC!9(HI9#;Y!M\C^B3]F;C]
MGGX*>WPR\'#Z8T2SH`_,#]BV%'_X*`_M3O+'&T$.C7YD>54,432>)+)$!:3A
M7;#@`<D!NP-`'[0[-+7YMM@I7#;MMN,;>0<XXQCKVQ0!=#(4#JRE"NY6!!0K
MC(8,.-N.]`'XO_M)_%'QE^VW\8XOV1?@)J4UK\-?#]]'<_&?XAV)+Z;-#870
M6YM([F,[)]-M;B)H8(0V+Z^7=AH+0%S]`.L_:V_X)Y>'_P#A4GA37_V=]'N-
M)^(?P9T*UAM;+3)6@UCQUHNCR'43*MW$5=_'=C?";4+"[!$DSO+9Y_>VY@-O
M*P;?(]H_8'_;&MOVB/!Q\$^-[R&V^,_@BQC36XI`ML?&6BV[+:1>+;"W8*4O
M5E"0:I9A0UM=$.%6*Y0(?@'Z'Z`:C?P:;9SWES(D,4$;NSR,J(@12S.[L0$C
M55+,QX55)/`HV_0-O*Q_-C^U+\2O$7[2_P"T`ND^!=,U#Q/#:3CP7\.-#TV,
MRW>L.TQN-3U@QG:MLEY>A[B2:9DCM[*S@>9XQ&^W]+RK"4<BR_FQ]6-"=1JI
M7DW>TK>Y2@EK*:CHDE\<I7LD>)7Q?-&>(P\)8F51^RP\(WM*U_>6UH.5Y2GH
MG"*:;5F?L+^QG^R/I/[-GA2;5]=^Q:Q\7?%UI`?&.O6_[VUTFT#+<P^$/#TT
MBAET>UG"M-/A6O;B,3.!'%;Q6_Q6<9K5S/$N=W'#4?<HT[6Y8)NS=KWG+>3;
M>K=K+?KR_!/!PJRJ253$XF;J59I67,]HQNVU"*5HJ^UNB27VO7DGH!0!S/C&
MP\3ZGX9UC3_!GB"S\*^)[NT,.C^(;_1H_$%KI-RSIF[DT:6ZMX[]EB$@6.24
M(&968.JE&`/R0F_X)5^,Y_%.J^-W_:C\2+XOUJ^O-2U3Q'#X4MX-6NKW4)#+
M>S2746K!E\QCC:FQ55510%4``;>5C:'_``3/^*PS_P`9B?$')&"?[*D!..F?
M^)WV]*`-KPK_`,$W/'NB^,O!7B;7OVI?&GBC3_"/B_0/%;Z'?Z2XM]1ET&]2
M\AMF<ZRWDEBI02;6V[B0IHV^0;?(_5B[A\^UN(>?WD,B`#@Y*D+^N*/P#;Y'
MXBZ;X6/PX_X*<>&Y=4@\K3?&^MZMXCT*XE7;%-/XF\&:U:2"-W`!FCU^VOH"
M%R0TT:_QC/V_MUB>$I*G/W\-&G2J)+5>SK1LFD]I4^5W>CU/*J7CC:479J%9
M25W9J-2C5C&W>T^:-E?2U[*R/W#KX@]4YSQAH=SXF\)>)O#EEJ1T:[U[0-7T
M:UU=;2*_.E7&I:?<6<.H"QG98KPV\DRR^3(P63R]K$!C0!\W?LA_LOG]EGP9
MXI\*2>-)?&\WB?Q;/XIFU*72(=&^SO/96MHUJMM!<3*PW6[2;]P_UNT#"\FW
MR#8^M*`/@G]KW]@WP7^U)J&C>*;77W^'GCS3;=M*U+Q+I^D6VIKXCT(1R"SL
M-:LI)H1/<V$[EK6[W^9''+-`VZ)D$1M\@_0^OOAGX-'P[^'O@KP&M^VJ#P?X
M9T;PZ-2:!;9K_P#LFQAL_M;6ZNXA,OE;]@9@N[&3BC;Y!M\C\P/$?_!,3Q=J
M_P`0/&/Q"TS]I77?#NK^+]:U+4[J71O"5IITR6][<M-!8/+9ZI'YD4$(@BSA
M=YA\QAN8T;>5@V^11O/^"8GQ/OK2[LKG]L'Q]-!>6L]I/')I$C))!<1/#+'(
MO]N?-&R.P*Y&02.]`'VYX[^!/Q*UGX&^%/@KX`^,LO@"/2O"=CX/\2>+8_#$
M6KZ_KNE66DV^EE-.N)M3B&@/<+#)YLL:S2[)MD<D14LQMY6#;Y&K^R]^S)X)
M_9=^'L?@WPPS:KK-_/\`VCXM\77=O'!J?B75B-HGF5&;[/9P1XB@M5=EB4'!
M+,23;Y!M\CZ4H`_-OXF?\$_[*^^/EG^T/\'OBC>_!?Q-'J,.O:CI^F^'K75]
M*O/$;2.NKZA';O=0;;/6K-FCU+3F5X;AWFFPKSN:-%Y6#;RL<C\=?C!\2OVD
M=;O_`-GC]F>`:XMJ5TGXK_%B%Y++P1X?7;Y6HZ)::V@D5I7=7^TBT-U/(NZU
MM4DQ+*GT^7X&CED*.:YNN16Y\-AFDZM1Z<M1P;LDDVXJ=ES6<FG9/S*U=XKF
MP^%M5@KQJ;J+LG[CG;E5.6GO1<G.-XQ5KR/J']F+]D?P!^S=H[7%D%\3?$/5
M+98O$/CK4+6..\>-MKOI.@VY+_V)H*R#/D)(\L[*)+J65@BQ>7F>:5\SJJ=7
MW*5-6A33?+'O)W>LY?:?R5D=5##1H^^[2K6MS6244MH4U]F"Z*[;ZMZ6^L:\
MPZ0H`*`"@#RGPG\4M/U:RUB7Q!'%X?N=&COK^4RNYL[S1+6[N+0:G8S2*&F5
M)K=X)8P"RRA0`?,446L'Z&SX$\87?BZ/6YKK2FTA=.U06MG;RL_VM[*:UAN[
M2:\C8#R+AX)XW,:Y"AP,Y!HV^0&59^)/'>M7NO)HFE>%C8:+XAU#00^I:AJD
M-U*;`PLTQCM[.1!NBG0\-]X$8P,DVL'Z&_XV\1:EX<L=)DTJTLKN^U;Q#I>@
MPQZA-/!:H^I>>JRR26Z.X"R1IT4\,>.*%^0'Q%^U7\*/&OBJW\'>/+32-"T#
MXA?#GQ-IOB#X?^,-)U6YGTVUUN+4+2ZC\-^*X;RSBEM/#FL7=K;0?;8VD2SN
M&BD=1%)+N]7*L>L%.M1JWE@L9!TJ\$KM)QE&-6/6]/F;Y4TY+2^QR8O#RK04
MJ+C3Q-.W).6UE*,G"5OLMQ3MM=:Z.1]6:7\6%USP'X?\7V.CSZ;J=]KNB>&_
M$?A?7%DM-6\)Z[<ZG;Z7KVB:I`HW)J&GW,DH1AF&XC\FYA>2VN8I'X*U'ZO6
MG2YXU%'X9P?NSBU>,HWU2DK.SU6S2::.BE-SIPFXN$I)-Q>\7U3]'H>A>)_$
M=KX7TIM1N(9[N5[BWL=.TZT"M=ZEJ5Y((;.QM@Q`\R20\L>%568YVX.)9S-K
MJ?Q1$MM<7WACPP;&::%9["SUVZ&K6-O(ZK)*T\]F+2ZEAC)=HXRF[851B2*>
MB^0;'H<\T5M#-<3R+#!!%)--*YVI%%$A>21R?NJJ*23V`I`<%\/_`!P?&=MJ
M3W%C_9=W9W22P6C%]\VAZ@AN=#U(B0`C[3:AB<#:&B;'!%&P&WJ^O3:;K_A7
M1XX(9(O$$VK13RN[K+;C3K#[6AA1>'+-\K;N@Z<T?H!K:K/?6MC)+IMO'<W:
MR6ZI!()"K))<112L1%\WR1.\G'_//GU!MY6`S]`U/5=16[_M/1Y-):V>**(2
M,["Z8HQFEAW1K^X#!0IZG)W`$<@'0T`%`$4TGDQ22A68HI8(@+,2.@"J"?RH
M`\'\9?#KQ9\73-HWBS7+[P=\-Y<Q7_AOPK?S6?BSQC:G*R66O>)[9E?PWH,R
M_+)I^CG[9<(Q6?48D9K<]F'Q%/"6JTZ2JXE:QE4BG3I-=8TW=5)KHZEX1>T&
MTF8U:4JJ4/:.G3^THZ2FMN5R=^6+5[\MI/2TE;7U;P?X,\*>`/#^G^%?!7A_
M2O#/A[2XA#8Z1HUG#8V=NH`!81PJ/,F;&7FD+R2'+2.S$DX5J];$5)5J]65:
MK+><VW+TN]DNB6BZ(TA"%**ITXJG".T8JR[;?(Z>LB@H`*`"@`H`\;\'>#-'
MU_PGX:?Q!I<C76AZUKUY9I<QRVT@WZ_J4@@N8944S6,I$$QAD4HYBB?D#DV\
MK`=#X+AGBUSXAO+!/"DWBI'@>6&6))HQI-@OF0-(@$T>X$;D++D$9R#1L'Z'
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M%M?L/$,.F>8(FU&&U6:"\LX6;"BY:UN)6BW$`NBCJ10M`_0K0?$[1KIX+6ST
M?Q9/J<TT4#:6?#6J07%J[RK$[7D]Q`EK!#%EG>3SV&V-BN[C+M8/T)/B0-0U
M#2K+PII:SI<^+K]=(N+R.VFFBTW2%C:YU>\G>/:D8^R1F%5D=-[7(53GHEI\
M@.6;0O$/@SQ)X>\276J#Q!8SK;^#]5BT_P`/QZ<]AI4Y8Z3=R0:?),)K>TU$
M1(SLBF**Y?G9G:U^0;&UX\O8M)\2^`-9N;;4)K/3KKQ#]I?3M.O=2D@%SI*0
M1;X;&&1P'E*J"1Z^AH7Y!MY':Z!XCT_Q);SW.G1ZC%';S_9W74M+O]*E,GEI
M+F.&_@B>2/:Z_.H*YR,Y!I;>5@-Z@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@
?`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
